When do Products Really Peak?
In recent years, many pharmaceutical companies have come to the conclusion that they're not generating enough new products. They anticipate sagging revenues if they go on marketing mostly the same older drugs, figuring that new offerings from competitors will quickly erode sales. But John Ansell, a pharmaceutical consultant based in Thame, near Oxford, UK, thinks companies have been underestimating the sales potential of drugs already on the market.
You may also be interested in...
Manufacturers Should Map Processes, Bolster Quality Culture To Tackle Data Integrity Problems in The Microbiology Lab
To reduce the opportunity for data integrity failures in the microbiology lab, manufacturers should map out the workflow so that activities and expectations for employees are clearly spelled out. Having formalized processes will ensure that employees don’t cut corners.
Companies can have their EU centralized marketing authorization application and submission for an Article 58 opinion (on medicines for use in non-EU countries) reviewed in parallel by the European Medicines Agency. The simultaneous assessment can be helpful when drugs and vaccines are needed for both EU and non-EU populations.
The coronavirus could have serious adverse effects on regulatory procedures at both European Medicines Agency and EU member state level. A new business continuity plan describes how procedures will be prioritized if problems arise.